UK markets close in 4 hours 41 minutes

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
44.29+0.94 (+2.17%)
At close: 04:00PM EDT
44.29 0.00 (0.00%)
After hours: 05:04PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
318,802
281,594
202,129
402,710
129,085
-
Depreciation & amortisation
84,605
84,856
49,641
2,997
3,284
-
Deferred income taxes
31,923
34,506
40,005
-155,434
0
-
Stock-based compensation
38,528
36,620
24,397
20,820
17,204
-
Change in working capital
-30,930
-38,671
-85,951
3,738
-108,366
-
Accounts receivable
-1,220
-3,339
-83,941
6,755
-38,288
-
Inventory
-59,867
-26,884
-17,481
7,371
-31,388
-
Other working capital
423,572
373,277
235,300
297,983
52,950
-
Other non-cash items
-4,731
-4,626
6,927
22,352
13,603
-
Net cash provided by operating activities
431,034
388,571
240,110
299,440
55,454
-
Cash flows from investing activities
Investments in property, plant and equipment
-7,462
-15,294
-4,810
-1,457
-2,504
-
Acquisitions, net
-
0
-999,120
0
-
-
Purchases of investments
-381,755
-292,911
-255,208
-652,515
-226,185
-
Sales/maturities of investments
269,789
211,296
746,127
247,683
305,967
-
Other investing activities
-
-
26,006
-
-
-
Net cash used for investing activities
-119,428
-96,909
-487,005
-406,289
78,354
-
Cash flows from financing activities
Debt repayment
0
-13,483
-447,453
-369,064
-19,560
-
Common stock issued
-
-
-
-
-
0
Common stock repurchased
-252,300
-402,383
-200,002
-350,058
-150,117
-
Other financing activities
-
-
-76,224
-424
-
-279
Net cash used provided by (used for) financing activities
-243,862
-407,987
362,371
77,865
-106,284
-
Net change in cash
67,744
-116,325
115,476
-28,984
27,524
-
Cash at beginning of period
96,883
234,695
119,219
148,203
120,679
-
Cash at end of period
164,627
118,370
234,695
119,219
148,203
-
Free cash flow
Operating cash flow
431,034
388,571
240,110
299,440
55,454
-
Capital expenditure
-7,462
-15,294
-4,810
-1,457
-2,504
-
Free cash flow
423,572
373,277
235,300
297,983
52,950
-